The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease

Clinical trial NCT06167681 · RECRUITING

Trial details

NCT number: NCT06167681
Sponsor: iRegene Therapeutics Co., Ltd.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Parkinson Disease

Start date: 2024-01-17
Primary completion: 2025-12-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.